OTL38, which is a folate receptor-alpha-targeted NIR tracer, has allowed for occult lesion detection in 48% of patients with ovarian cancer that would have otherwise been missed using current conventional techniques. This evidence concerns the gene FOLR1 and ovarian carcinoma.